Secukinumab
Secukinumab
Secukinumab (pronounced as seh-koo-kih-noo-mab) is a human monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is marketed under the trade name Cosentyx by Novartis.
Etymology
The name Secukinumab is derived from its function. The prefix "secu-" is derived from the Latin word "secare", meaning "to cut", and "-kinumab" is a suffix used in names of monoclonal antibodies. The name implies that the drug cuts off the function of a specific protein in the body.
Usage
Secukinumab is used to treat moderate to severe plaque psoriasis in adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light, alone or with systemic therapy). Secukinumab is also used to treat adults with active psoriatic arthritis and active ankylosing spondylitis.
Mechanism of Action
Secukinumab works by binding to a protein (interleukin-17A) in the body and blocking its activity. This protein is involved in inflammation processes and by blocking it, secukinumab can reduce inflammation and other symptoms of the diseases it is used to treat.
Side Effects
Common side effects of secukinumab include cold symptoms, diarrhea, and upper respiratory infections. Serious side effects can include allergic reactions, infections, and inflammation of the bowel (inflammatory bowel disease).
Related Terms
External links
- Medical encyclopedia article on Secukinumab
- Wikipedia's article - Secukinumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski